PMEF
ELVN icon

Point72 Middle East FZE’s Enliven Therapeutics ELVN Stock Holding History

Point72 Middle East FZE’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-293
Closed -$6.42K – 1685
2023
Q1 		$6.42K Buy
+293
New +$5.96K ﹤0.01% 1507

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Middle East FZE's ELVN Position: Q2 2023 in Review

Point72 Middle East FZE sold out of Enliven Therapeutics (ELVN) in Q2 2023, closing a stake of 293 shares — an estimated $6.42K sold.

Point72 Middle East FZE first reported a position in ELVN in Q1 2023 and held it in 1 quarter. The position peaked at $6.42K in Q1 2023. 63 funds tracked by Wall St. Rank hold ELVN as of Q2 2023.

  • Point72 Middle East FZE reported no remaining Enliven Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 293 Enliven Therapeutics shares in Q2 2023, an estimated $6.42K.
  • Point72 Middle East FZE first reported a position in Enliven Therapeutics in Q1 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Enliven Therapeutics position peaked at $6.42K in Q1 2023.
  • 63 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2023.

Based on Point72 Middle East FZE's 13F filing for Q2 2023, filed 14 Aug 2023.